中证沪港深创新药产业指数上涨4.05%

Core Viewpoint - The SHS Innovation Drug Index has shown significant growth, with a 21.77% increase over the past month, 33.51% over the past three months, and 50.42% year-to-date, indicating a strong performance in the innovative drug sector in both mainland China and Hong Kong [1]. Group 1 - The SHS Innovation Drug Index opened lower but closed higher, rising by 4.05% to 2435.18 points, with a trading volume of 68.919 billion yuan [1]. - The index is composed of up to 50 representative securities from the mainland and Hong Kong markets, focusing on companies involved in innovative drug research and production [1]. - The index was established on December 31, 2014, with a base point of 1000.0 [1]. Group 2 - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [1]. - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [1]. - The index will be adjusted if a sample company is delisted or if there are significant corporate changes such as mergers or acquisitions [1]. Group 3 - Public funds tracking the SHS Innovation Drug Index include various ETFs and fund products from institutions like Guotai, Xizang Dongcai, and Fuguo [2].